



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## CDK9-IN-7

<b>Cat. No.:</b>	HY-126251		
<b>CAS No.:</b>	2369981-71-3		
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>37</sub> N <sub>7</sub> O <sub>2</sub> S		
<b>Molecular Weight:</b>	547.71		
<b>Target:</b>	CDK; Apoptosis		
<b>Pathway:</b>	Cell Cycle/DNA Damage; Apoptosis		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 62.5 mg/mL (114.11 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	1.8258 mL	9.1289 mL	18.2578 mL
		5 mM	0.3652 mL	1.8258 mL	3.6516 mL
10 mM		0.1826 mL	0.9129 mL	1.8258 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.80 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.80 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC <sub>50</sub> =11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC <sup>[1]</sup> .		
<b>IC<sub>50</sub> &amp; Target</b>	CDK9/cyclinT1 11 nM (IC <sub>50</sub> )	CDK4/cyclin D 148 nM (IC <sub>50</sub> )	CDK6/cyclinD 145 nM (IC <sub>50</sub> )
<b>In Vitro</b>	CDK9-IN-7 displays exceptional potency against NSCLC cell lines, especial A549 and H1299 with IC <sub>50</sub> values less than 0.5 μM. In the drug-resistant NSCLC cell line H1975, CDK9-IN-7 also exhibits good inhibition potency with an IC <sub>50</sub> value of 0.837 μM <sup>[1]</sup>		

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA